Medicine and Computers

Use of a viewdata system to collect data from a multicentre clinical trial in anaesthesia

H A WALDRON, R F COOKSON

Abstract

The interactive electronic information storage and transmission system PRESTEL was assessed as a method of recording and collecting patient record forms from a multicentre trial in anaesthesia. PRESTEL terminals were provided in anaesthetic centres around Britain and all data handled by this public viewdata service, which connects users by telephone to a central computer. The trial was of a new analgesic supplement, alfentanil, and confirmed more rapid recovery of patients as compared with that after traditional anaesthesia with halothane. Advantages of the system were manifold and included reducing the need for the trial monitor to visit the trialist, an electronic “mailbox,” confidentiality, and the ability immediately to identify violations of study protocol. No participant found the system too difficult to use, though the small keyboard was a source of complaint. Despite the initial cost of the system its utility vastly outweighs traditional methods of data collection.

Introduction

Viewdata is an interactive electronic information storage and transmission system which connects users by telephone to a central computer. British Telecom invented the system and now market PRESTEL, the world’s first public viewdata service. Other countries have viewdata systems, although PRESTEL remains by far the largest in terms of breadth and quantity of information and its thousands of customers. In Britain emphasis was placed initially on a nationally available system. By contrast, in Western Germany a more geographically limited service (BILDSCHIRMTEXT) was introduced, emphasising a wide range of services (shopping, banking, etc) of interest to private subscribers. These facilities will gradually be introduced on PRESTEL, although up to now British Telecom have concentrated on the business and professional communities.

In the wake of travel agents and stockbrokers, the medical profession has been identified as a coherent group whose information needs may be amenable to handling by PRESTEL. An early example of this is the joint project between the BMJ and Glaxo to publicise job vacancies and the contents page of the journal. PRESTEL compatible computers have become increasingly available in hospitals and the viewdata approach is now being used to provide access to information on drugs and poisons.

In late 1982 Janssen Pharmaceutical Ltd donated a number of PRESTEL terminals to departments of anaesthesia in the United Kingdom to facilitate access by anaesthetists to its technical information service. We have investigated the utility of the system “in reverse” to collect data from a multicentre study on the new narcotic analgesic alfentanil.

Multicentre trials

Registration and marketing of a drug may be achieved after a small number of good quality trials. Nevertheless, the eventual role of a new drug in clinical practice is dependent on, and can therefore only be defined by, its performance characteristics when used routinely by a representative sample of clinicians. Large multicentre trials provide an essential step between controlled studies in centres specialising in clinical research and the routine use of a therapeutic agent after marketing. This step is particularly important in anaesthesia: anaesthetics are not normally given according to a fixed dosage schedule, and usage of drugs may vary widely depending on the anaesthetist’s assessment of the patient and the variable stresses related to the surgical conditions. In order to allow for variations among anaesthetists we organised a multicentre study with as many centres as was practicable, each centre contributing a minimum of 20 patients.

The study was designed to compare speed of recovery after the use of alfentanil and halothane as supplements to methohexitone-nitrous oxide anaesthesia in minor surgical procedures. The volume of data to be collected and the geographical spread of the participating centres made it logical to consider a PRESTEL based system for collecting the patient record forms.

Methods

VIEWDATA

Each participating centre used a PRESTEL terminal comprising a keyboard (Tandata Marketing Ltd) and a red-green-blue monitor (Microvitec) (fig 1). These were connected by addition of a jack socket to the hospital telephone system to allow automatic dialling to the local PRESTEL computer node. To ensure confidentiality each set was registered as a member of a closed user group, and to activate the system once connected to PRESTEL a personal password had to be entered. The nature of the system is such that once a patient record had been entered and dispatched it could be examined only by the trial monitors.

Vismed Ltd, Maidenhead, wrote the software and monitored the record forms as they were received. A menu offered the investigator three choices on access to the reporting system. A summary of the trial protocol (four frames) was available for reference as the first option. The second item allowed transmission of data on individual patients (eight frames per patient). The third choice gave a free format “help” page, which allowed the anaesthetist to type in comments or messages which could then be transmitted instantly to Vismed or the Janssen trial monitor with the opportunity of a response the same day.

The anaesthetist entered data by selecting the appropriate starting point from the menu and then typing details of the patient on a form organised electronically to ensure that sections were completed in a predetermined sequence (fig 2). Different colours were used to separate and identify spaces for data entry and to contrast with headings and instructions. The action of calling the record form automatically recorded the investigator or centre by name and the date and time of data entry. On completion of each form the data were transmitted to the central computer. Incorrectly entered data could be modified easily by the anaesthetist before transmission. The data
were stored on the PRESTEL central computer and were available instantly for access by the trial monitor. In this study forms were downloaded on to an Apple IIe computer with an Owl Editel system for sequential checking and validation. Forms were stored as Pascal files on floppy discs. Analysis was performed separately on an IBM System 38.

ANAESTHETIC TECHNIQUE

Thirty nine anaesthetic centres contributed data to the trial and the protocol was approved by the local ethical committee in each case. The study group comprised 907 patients who underwent minor general, gynaecological, or urinary tract procedures that did not entail cutting the skin. All gave informed consent to the investigation and breathed spontaneously throughout. Within each centre patients were allocated at random to receive either alfentanil or halothane. According to the anaesthetist’s preference, patients were either not premedicated or given lorazepam 1 mg by mouth two hours before induction or temazepam 20 mg by mouth one hour before induction. In the alfentanil group the anaesthetic sequence was intravenous alfentanil 500 μg given slowly, followed immediately by 1% methohexitone until the eyelash reflex was obtunded. Patients then breathed 66% nitrous oxide ir oxygen. The anaesthetist gave methohexitone in increments of 1 ml or alfentanil in increments of 200 μg according to clinical requirements. If apnoea occurred (defined as no inspiration for at least 30 seconds) respiration was assisted manually. In the halothane group induction was with methohexitone and the patients breathed 66% nitrous oxide in oxygen. Halothane was given as required during maintenance. Recovery of consciousness was assessed by noting the time taken from discontinuation of nitrous oxide for the patient to respond correctly to “What is your name?” followed by “Show me your left thumb.”

STATISTICAL ANALYSIS

All data are quoted as mean and standard error of the mean (SEM). The 2 × 2 χ² test was used when comparing sex, ASA grade, and incidence of apnoea. The unpaired Student’s t test was used for all other variables. The two indices of recovery showed a skewed distribution, and statistical analysis was therefore performed on logarithmically transformed data.

Results

Of the 907 patients who entered the study, 643 were included in the analysis; 297 were given alfentanil and 346 halothane. The remaining patients were excluded because either the anaesthetist did not follow the protocol (219 cases) or the record form was incomplete (45).

Full details of the patients, types of surgery, and course of the anaesthetic are available on request to the authors. An extended summary of the data is also available on PRESTEL, page 7104. The treatment groups were comparable. The mean durations of anaesthesia were 10-92 (SEM 0-45) minutes (alfentanil) and 11-95 (0-33) minutes (halothane). During maintenance, 211 (71%) of the patients given alfentanil required increments of the drug, the first after a mean of 4-58 (SEM 0-21) minutes. Apnoea requiring manually assisted ventilation occurred more frequently in the alfentanil group. At induction 56 patients (19%) given alfentanil became apnoeic compared with only five of the patients (1-4%) given halothane (p = 0-001). Apnoea during maintenance occurred in 54 (11-5%) and one (0-3%) of the patients in the two treatment groups, respectively (p = 0-001). The table summarises the recovery data. Recovery was significantly faster in the alfentanil group, the patients responding with their correct name in less than half the time taken by the halothane group (p = 0-001). Similar significant differences were seen in the time taken to show the left thumb, recovery times being 4-21 (SEM 0-25) minutes and 9-46 (0-29) minutes, respectively. Premedication had a pronounced effect on both indices of recovery, lorazepam delaying recovery more than temazepam.

Mean recovery times (minutes) from discontinuation of nitrous oxide to giving correct name. (SEM in parentheses)

<table>
<thead>
<tr>
<th>Premedication</th>
<th>Lorazepam</th>
<th>Temazepam</th>
<th>None</th>
<th>All patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfentanil</td>
<td>4-96 (0-59)</td>
<td>3-45 (0-29)</td>
<td>2-58 (0-26)</td>
<td>3-75 (0-24)</td>
</tr>
<tr>
<td></td>
<td>[n = 92]</td>
<td>[n = 150]</td>
<td>[n = 55]</td>
<td>[n = 297]</td>
</tr>
<tr>
<td>Halothane</td>
<td>9-97 (0-66)</td>
<td>8-49 (0-39)</td>
<td>6-44 (0-41)</td>
<td>8-57 (0-29)</td>
</tr>
<tr>
<td></td>
<td>[n = 166]</td>
<td>[n = 68]</td>
<td>[n = 62]</td>
<td>[n = 346]</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>p &lt; 0-001</td>
<td>p &lt; 0-001</td>
<td>p &lt; 0-001</td>
<td>p &lt; 0-001</td>
</tr>
<tr>
<td>Halothane</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Discussion

ADVANTAGES OF VIEWDATA

Viewdata collection and transmission of clinical trial data minimized the problems of handling a large volume of information from 39 geographically well separated centres in Great Britain. Classically a trial monitor would visit each participant several times during the study, a process costly of time, much of it wasted in travel. The opportunity to cut down on these visits was a major reason for using viewdata technology. Costs of travel thus saved must be set against the fee for installing PRESTEL in each centre (£15) and the quarterly PRESTEL bill (including rental: roughly £30). During the study Janssen paid these costs and the telephone connections were routed, with permission, through the hospital switchboard.

A particular cost saving feature of the system allows the use of local, as opposed to trunk, rates for the telephone connection of most PRESTEL terminals to the central computer. Regrettably, the most useful telephone based feature of the system, the electronic “mailbox,” entailed trunk calls to London. This telephone message service was shorty to be made available to most subscribers on a local call basis. The electronic mailbox allows each

![FIG 1—Tandata keyboard and Microvitec monitor.](image1)

![FIG 2—PRESTEL frame showing typical example of a patient record form.](image2)
user to leave messages for any other user at a time that is convenient for the sender. The recipient is alerted to waiting messages whenever he connects his terminal to PRESTEL. During this study extensive use of this facility by the anaesthetists and trial monitor permitted rapid trouble shooting, providing the clinician with convenient, fast responses to his queries and requests.

By providing clear, typewritten record forms to the central co-ordinator, the viewdata system avoids the problems of ambiguities and misunderstandings which may result from illegible handwriting. This proved of great benefit in checking data and identifying violations of protocol. In addition, the electronic nature of the system provides the twin advantage of speed and confidentiality when compared with the postal system. Rapid data collection gave a useful indicator on a daily basis of the rate of progress for each centre in the study. The daily updating feature of the system might be of major advantage in trials with a sequential analytical design. To maintain confidentiality each participant was made a member of a closed user group, and only these people could summon the trial protocol and record forms. Individual patients were identified by their initials only, together with a trial number (fig 2). In addition, only the central co-ordinator could obtain access to the data once transmitted. Each centre thus proceeded independently without knowing the results obtained by the other trialists.

DISADVANTAGES AND IMPROVEMENTS TO SYSTEM

Enthusiasm for new technology was a major motivating force for many of the investigators, as well as ourselves, but some were daunted by the apparent complexity of this substitute for pen and paper. Nevertheless, no trialist gave incompleteness with the results obtained with the PRESTEL system and making it work: S Allen, K Birkinshaw, D Burt, P Cartwright, N Coote, J Curran, D Desgrands, R Dunnill, H Fischer, A Florence, H Freedman, J Fryer, N Goodman, H Gordon, J Henney, G Hibbert, J Jellicoe, M Johnson, R Johnston, S Jothilingam, B Kay, S Lowe, K Macleod, J Martin, A MacDonald, A Mellon, C Nixon, O Plantivan, E Proctor, J Sears, G Smith, C Spanswick, J Thorn, S Tinolai, M Watt, G Weetch, E Welchew, J Windsor, C Wright.

References


(Accepted 31 July 1984)

How frequent is postinfluenzal depression?

Although it has generally been believed that influenza, and other common viral diseases such as infectious mononucleosis and hepatitis, are followed by an increased incidence of depression, hard evidence of the link and its frequency is lacking. Part of the problem lies in the resemblance between the physical debility and fatigue that may follow some viral and bacterial infections and the more clear cut effective symptoms of mild depression. There is a borderland of mild dysphoria, in which it is hard to make distinctions, particularly in retrospect. A recent study of psychiatric patients found no evidence of increased influenzal antibody titles in depressive illness, although a follow up of patients with infectious mononucleosis showed an increase in symptoms of mild depression and anxiety. Nevertheless, clinical experience suggests that after influenza there is an increased incidence of a more severe depression, which contrasts with the milder symptoms that may follow other infections. There may also be a previous or family history of depression, suggesting that the patient is predisposed. Both the clinical picture, which may show preoccupation, guilt, and self-recrimination, and treatment response resemble those of other severe endogenous depressions. — S Paykel, professor of psychiatry, London.